Susquehanna International Group
PDSB icon

Susquehanna International Group’s PDS Biotechnology PDSB Stock Holding History

Susquehanna International Group’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32K Buy
36,328
+14,276
+65% +$15.2K ﹤0.01% 12943
2026
Q1 		$13.3K Sell
22,052
-16,514
-43% -$12.4K ﹤0.01% 12910
2025
Q4 		$29.7K Sell
38,566
-55,778
-59% -$50.3K ﹤0.01% 11878
2025
Q3 		$95.3K Buy
94,344
+80,937
+604% +$95.1K ﹤0.01% 11594
2025
Q2 		$17.8K Sell
13,407
-12,346
-48% -$16.8K ﹤0.01% 12352
2025
Q1 		$30.6K Sell
25,753
-221,224
-90% -$315K ﹤0.01% 12002
2024
Q4 		$403K Buy
246,977
+112,717
+84% +$298K ﹤0.01% 9198
2024
Q3 		$513K Sell
134,260
-1,195
-0.9% -$3.99K ﹤0.01% 8410
2024
Q2 		$397K Sell
135,455
-53,711
-28% -$172K ﹤0.01% 8813
2024
Q1 		$749K Sell
189,166
-72,052
-28% -$371K ﹤0.01% 7557
2023
Q4 		$1.3M Buy
261,218
+80,681
+45% +$401K ﹤0.01% 6349
2023
Q3 		$912K Buy
180,537
+24,585
+16% +$135K ﹤0.01% 6834
2023
Q2 		$784K Sell
155,952
-59,126
-27% -$387K ﹤0.01% 7244
2023
Q1 		$1.32M Buy
215,078
+96,915
+82% +$793K ﹤0.01% 6114
2022
Q4 		$1.56M Buy
118,163
+59,070
+100% +$417K ﹤0.01% 5193
2022
Q3 		$176K Sell
59,093
-92,007
-61% -$390K ﹤0.01% 11021
2022
Q2 		$552K Buy
151,100
+14,310
+10% +$68K ﹤0.01% 8026
2022
Q1 		$846K Sell
136,790
-160,510
-54% -$997K ﹤0.01% 7570
2021
Q4 		$2.41M Sell
297,300
-38,078
-11% -$410K ﹤0.01% 5076
2021
Q3 		$5M Buy
335,378
+208,047
+163% +$2.59M ﹤0.01% 3964
2021
Q2 		$1.6M Buy
+127,331
New +$994K ﹤0.01% 6471
2019
Q1 		– Sell
-4,761
Closed -$39.7K – 9577
2018
Q4 		$31K Buy
4,761
+3,983
+512% +$52.7K ﹤0.01% 8604
2018
Q3 		$13K Buy
+778
New +$14K ﹤0.01% 9032
2018
Q2 		– Sell
-1,895
Closed -$45K – 10177
2018
Q1 		$45K Buy
+1,895
New +$510K ﹤0.01% 8985
2017
Q1 		– Sell
-1,312
Closed -$328K – 9687
2016
Q4 		$328K Buy
+1,312
New +$298K ﹤0.01% 7808
2016
Q1 		– Sell
-923
Closed -$231K – 9487
2015
Q4 		$231K Buy
+923
New +$298K ﹤0.01% 8181

Other funds holding PDSB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
MCM
Militia Capital Management Austin, Texas $3.37B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Susquehanna International Group's PDSB Position: Q2 2026 in Review

Susquehanna International Group increased its PDS Biotechnology (PDSB) stake by 65% in Q2 2026, buying an estimated $15.2K and bringing the position to 36,328 shares worth $32K. The position accounts for ﹤0.01% of the portfolio, ranked #12943.

Susquehanna International Group first reported a position in PDSB in Q4 2015 and has held it in 26 quarters since. The position peaked at $5M in Q3 2021. 52 funds tracked by Wall St. Rank hold PDSB as of Q2 2026.

  • Susquehanna International Group held 36,328 shares of PDS Biotechnology worth $32K as of Q2 2026.
  • Susquehanna International Group bought 14,276 PDS Biotechnology shares in Q2 2026, an estimated $15.2K.
  • PDS Biotechnology made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #12943 holding.
  • Susquehanna International Group first reported a position in PDS Biotechnology in Q4 2015 and has held it in 26 quarters since.
  • Susquehanna International Group's PDS Biotechnology position peaked at $5M in Q3 2021.
  • 52 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.